Wells Fargo & Company Altimmune, Inc. Transaction History

Wells Fargo & Company

$407 Billion
Q2 2024

A detailed history of Wells Fargo & Company transactions in Altimmune, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 84,762 shares of ALT stock, worth $575,533. This represents 0.0% of its overall portfolio holdings.

Number of Shares

84,762

Previous 58,942 43.81%

Holding current value

$575,533

Previous $600,000 6.17%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$5.91 - $10.23 $152,596 - $264,138	25,820 Added 43.81%	84,762 $563,000
Q1 2024 May 10, 2024	BUY	$8.22 - $13.81 $112,868 - $189,625	13,731 Added 30.37%	58,942 $600,000
Q4 2023 Feb 09, 2024	SELL	$2.14 - $11.62 $206,381 - $1.12 Million	-96,440 Reduced 68.08%	45,211 $508,000
Q3 2023 Nov 13, 2023	BUY	$2.4 - $3.45 $252,986 - $363,667	105,411 Added 290.87%	141,651 $368,000
Q2 2023 Aug 15, 2023	SELL	$3.45 - $5.97 $184,564 - $319,377	-53,497 Reduced 59.62%	36,240 $127,000
Q1 2023 May 12, 2023	BUY	$4.19 - $16.83 $360,474 - $1.45 Million	86,032 Added 2322.05%	89,737 $378,000
Q4 2022 Feb 13, 2023	SELL	$8.74 - $16.45 $15,557 - $29,281	-1,780 Reduced 32.45%	3,705 $60,000
Q3 2022 Nov 14, 2022	SELL	$10.67 - $22.41 $11,470 - $24,090	-1,075 Reduced 16.39%	5,485 $70,000
Q2 2022 Aug 12, 2022	SELL	$3.94 - $11.77 $20,732 - $61,933	-5,262 Reduced 44.51%	6,560 $76,000
Q1 2022 May 16, 2022	SELL	$5.9 - $9.45 $94,742 - $151,748	-16,058 Reduced 57.6%	11,822 $72,000
Q4 2021 Feb 14, 2022	SELL	$8.69 - $12.48 $96,215 - $138,178	-11,072 Reduced 28.42%	27,880 $255,000
Q3 2021 Nov 15, 2021	SELL	$8.43 - $16.81 $1.19 Million - $2.37 Million	-140,883 Reduced 78.34%	38,952 $441,000
Q2 2021 Aug 16, 2021	SELL	$9.85 - $16.46 $244,260 - $408,175	-24,798 Reduced 12.12%	179,835 $1.77 Million
Q1 2021 May 13, 2021	SELL	$12.71 - $24.31 $49,721 - $95,100	-3,912 Reduced 1.88%	204,633 $2.89 Million
Q4 2020 Feb 09, 2021	BUY	$7.84 - $14.22 $1.2 Million - $2.18 Million	153,447 Added 278.5%	208,545 $2.35 Million
Q3 2020 Nov 05, 2020	BUY	$9.93 - $33.26 $544,263 - $1.82 Million	54,810 Added 19031.25%	55,098 $727,000
Q2 2020 Aug 13, 2020	BUY	$2.9 - $10.71 $582 - $2,152	201 Added 231.03%	288 $3,000
Q1 2020 May 14, 2020	BUY	$1.69 - $3.8 $147 - $330	87 New	87 $0

Others Institutions Holding ALT

# of Institutions

190

Shares Held

42.2M

Call Options Held

1.05M

Put Options Held

582K

View Full List

About Altimmune, Inc.

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $333M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

More about ALT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Altimmune, Inc. Transaction History